Is ZYN Safer Than Cigarettes? The FDA Is Officially Weighing In

Philip Morris International wants the FDA to let it say, in plain marketing language, that switching from cigarettes to ZYN nicotine pouches lowers your risk of lung cancer, heart disease, stroke, and mouth cancer. The FDA is now formally considering that request, and its own preliminary review suggests the science may actually back it up.

This is one of the biggest regulatory questions in the nicotine pouch space right now. The outcome could change how ZYN is marketed, how consumers think about it, and what the bar looks like for the rest of the industry. Here's what's happening and what it means.

What Is a Modified Risk Tobacco Product Application?

An MRTP application is a request to the FDA to allow a tobacco or nicotine product to be sold with specific health-related marketing claims. Unlike the standard PMTA process, which just asks "can this product stay on the market," an MRTP application asks for something more: permission to tell consumers the product is less risky than alternatives.

The bar for getting an MRTP authorized is high. The company has to show that the reduced-risk claim is scientifically accurate, that it won't mislead consumers, and that allowing the claim will benefit public health overall. That last part is the tricky one. Even if the product is genuinely less harmful, the FDA has to weigh whether marketing it as such might cause more people to start using nicotine who otherwise wouldn't.

ZYN's manufacturer, Philip Morris International (which acquired the brand's parent company Swedish Match in 2022), is asking the FDA to authorize specific claims for its ZYN nicotine pouches. Specifically, it wants to say that switching from cigarettes to ZYN reduces exposure to harmful chemicals and lowers the risk of serious smoking-related diseases.

What PMI Is Claiming and What the Science Shows

PMI's testing found that 36 out of 42 known cancer-causing chemicals present in conventional tobacco products were either completely undetected in ZYN or present at extremely low levels. For the remaining six chemicals, FDA reviewers concluded that the amounts were "below the level that would be expected to pose a health risk."

That's a significant finding, and the FDA's own preliminary assessment acknowledged it. In reviewing PMI's MRTP application, the FDA stated that the claim that ZYN lowers the risk of smoking-related diseases appears to be "scientifically accurate."

To be clear: ZYN is not harmless. Nicotine itself carries risks, including cardiovascular effects and addiction. But the specific diseases most closely associated with cigarette smoking, particularly lung cancer and other cancers caused by combustion, are driven by the burning of tobacco and the chemicals that combustion produces. ZYN doesn't burn anything. It delivers nicotine through a pouch placed under the lip, with no combustion and no tobacco leaf.

ZYN vs Cigarettes: The Core Comparison

Comparing ZYN to cigarettes isn't about whether ZYN is "safe" in an absolute sense. It's about relative risk. Cigarettes kill roughly 480,000 people per year in the United States, making them the leading cause of preventable death. They do this primarily through the chemicals produced when tobacco burns, including dozens of known carcinogens.

ZYN doesn't involve combustion. The pouch sits between your gum and lip and releases nicotine through saliva absorption. There's no smoke, no tar, and no burning chemicals entering the lungs. The risk profile is fundamentally different from cigarettes.

That doesn't mean ZYN is without risk. The nicotine it delivers is addictive. There are open questions about long-term oral health effects and cardiovascular impact over time, particularly for heavy users. Researchers are also still studying what chronic nicotine pouch use looks like over decades, because these products simply haven't been around long enough to generate that data.

But if you're comparing ZYN to cigarettes specifically, the scientific consensus is fairly consistent: the risk is substantially lower. The MRTP process is essentially the FDA's way of deciding whether that comparison can be made explicitly in marketing.

The FDA Advisory Committee Meeting

In January 2026, the FDA convened an advisory committee meeting specifically to review PMI's MRTP application for ZYN nicotine pouch products. Advisory committee meetings are non-binding, but they give the FDA expert outside opinions that often influence the final decision.

The meeting generated significant public attention and a range of submitted comments. Tobacco harm reduction advocates pushed for approval, arguing that telling smokers ZYN is less risky is true and potentially life-saving information. Public health organizations pushed back, arguing that flavored nicotine products are already driving youth addiction at alarming rates, and that authorizing reduced-risk marketing would accelerate that trend.

The FDA hasn't issued its final decision yet. These reviews take time. But the fact that the agency's preliminary scientific review was generally favorable to PMI's claims suggests the decision is genuinely in play.

The Youth Use Problem

The strongest argument against approving ZYN's MRTP application has nothing to do with the chemistry. It's about who is actually using the product.

According to the 2024 National Youth Tobacco Survey, approximately 480,000 middle and high school students reported current use of nicotine pouches. Of those, more than 22% said they used them daily. That's a significant youth population using a product that its manufacturer markets as an adult alternative to cigarettes.

Public health researchers point out that most of these young users are not switching from cigarettes. They're using nicotine pouches as their first nicotine product. This is the exact pattern that critics worry an MRTP authorization would accelerate: if ZYN can be marketed as "lower risk," it may be perceived as safer to start using, rather than just safer to switch to.

PMI has pushed back on this framing, arguing that the reduced-risk claim is specifically about current smokers switching, not about attracting new users. The company argues that accurate scientific information helps adults make better decisions about their nicotine use.

The FDA has to weigh both sides. Its MRTP standard requires the agency to find that the authorization would be "appropriate for the protection of the public health" taking into account the whole population, not just adult smokers who might benefit.

What "Zynfluencers" Have to Do With It

One factor complicating PMI's case is the rise of ZYN-related social media content. Over the past two years, a wave of creators on TikTok, YouTube, and other platforms have posted content showing ZYN use in appealing ways, often with large youth audiences. The term "zynfluencer" has been coined to describe this trend.

Critics argue this influencer ecosystem effectively markets ZYN to people who were never cigarette smokers, directly contradicting the stated purpose of an MRTP authorization. If the reduced-risk claim gets approved, the concern is that it gets layered on top of an already-viral product that appeals heavily to young people.

PMI has publicly stated it does not sanction this kind of marketing and that it supports measures to prevent youth access. But the company doesn't control what independent creators post about its products.

What This Means If You're a Current ZYN User

If you already use ZYN, the MRTP decision won't change the product itself. The pouches stay the same either way. What changes is whether the packaging and advertising can make explicit statements about reduced risk compared to cigarettes.

If PMI gets the authorization, expect to see claims like "switching to ZYN can reduce your risk of lung cancer and heart disease" in marketing materials. That's a significant shift from how nicotine alternatives have traditionally been marketed in the US, where tobacco companies are heavily restricted in what health claims they can make.

If the FDA denies the application, ZYN continues to be sold with its existing PMTA authorization, just without the modified risk claims. PMI could revise and resubmit with additional evidence.

How This Compares to What's Happened in Other Countries

The US is not the only country wrestling with how to position nicotine pouches relative to cigarettes. In Sweden, where the product category originated in the form of snus, public health authorities have long distinguished between tobacco-derived products (like snus) and tobacco-free nicotine pouches, with different regulatory approaches for each.

The UK's approach to tobacco harm reduction has generally been more permissive than the US system. Public Health England (now UK Health Security Agency) has endorsed the principle that non-combustible nicotine products are substantially less harmful than cigarettes, and that communicating this to smokers is a legitimate public health strategy.

The FDA's decision will be watched internationally as a signal of how the US plans to handle the harm reduction framing of nicotine products more broadly.

The Bigger Picture for Nicotine Pouches

Whether or not PMI's MRTP application succeeds, the fact that the FDA is seriously reviewing it marks a shift. The agency is engaging directly with the question of whether nicotine pouches can be positioned, officially and publicly, as a less harmful alternative to cigarettes.

That's a significant departure from the cautious, evidence-gathering posture the FDA has taken with tobacco products for years. It reflects the growing body of research on nicotine pouches and a recognition that millions of smokers are already making the switch anyway, with or without official guidance.

For people who use nicotine pouches or are thinking about switching from cigarettes, the underlying science is increasingly clear even without an MRTP label on the box. ZYN and products like it deliver nicotine without combustion. The chemicals that cause most smoking-related cancers aren't present in meaningful quantities. That's not a marketing claim. It's chemistry.

The MRTP decision will determine whether PMI gets to say that on the box. The science is already on the table.

Frequently Asked Questions About ZYN, the FDA, and Modified Risk Claims

Is ZYN FDA approved?

Yes, partially. The FDA authorized 20 ZYN nicotine pouch products for marketing through the standard PMTA process in 2025, meaning they can legally be sold in the US. What PMI is now seeking through its MRTP application is additional authorization to market ZYN with specific reduced-risk claims compared to cigarettes. That decision is still pending.

What does "modified risk tobacco product" mean?

A modified risk tobacco product is one that the FDA has authorized to be sold with specific health-related marketing claims, such as "this product poses less risk of harm than cigarettes." Companies need separate authorization to make these claims, beyond the standard approval to sell a product. The FDA evaluates both the accuracy of the claim and its likely effect on the overall population.

Is ZYN safer than cigarettes?

Based on current scientific evidence, the general consensus is that ZYN poses substantially less risk than cigarettes, particularly for the diseases most closely linked to smoking such as lung cancer. ZYN involves no combustion, which removes the primary source of tobacco-related carcinogens. However, ZYN still delivers addictive nicotine and carries its own risks, especially for young people and those with cardiovascular conditions. The FDA's own preliminary review found PMI's reduced-risk claim to be "scientifically accurate."

What specific health claims does Philip Morris want to make about ZYN?

PMI is seeking authorization to say that switching completely from cigarettes to ZYN can reduce users' exposure to harmful chemicals and lower their risk of serious smoking-related diseases including lung cancer, heart disease, stroke, and mouth cancer.

What did PMI's chemical testing find?

PMI's testing found that 36 out of 42 known cancer-causing chemicals found in tobacco products were either undetected in ZYN or present at extremely low levels. FDA reviewers concluded that the remaining six chemicals were present at amounts "below the level that would be expected to pose a health risk."

What was the FDA's preliminary finding on ZYN's MRTP application?

The FDA's preliminary scientific review concluded that PMI's claim that ZYN lowers the risk of smoking-related diseases appears to be "scientifically accurate." This is not a final decision, but it is a significant early signal that the application may have merit.

When will the FDA make a final decision on ZYN's MRTP application?

No specific timeline has been announced. The FDA convened an advisory committee meeting in January 2026 to gather expert input. A final decision could come later in 2026, though FDA regulatory timelines often extend beyond initial estimates.

Are there other nicotine products with MRTP authorization in the US?

Yes. Some smokeless tobacco products, including certain snus products from Swedish Match (now part of PMI), have previously received MRTP authorizations. Nicotine pouches, being a newer product category, are going through this process for the first time.

Why are some public health groups opposing ZYN's MRTP application?

The primary concern is youth use. Around 480,000 US middle and high school students currently use nicotine pouches, with more than 22% using them daily. Critics argue that authorizing reduced-risk marketing could make the product seem safer to start using rather than just safer to switch to, potentially accelerating youth nicotine addiction.

What happens if the FDA denies the MRTP application?

ZYN products remain on the market under their existing PMTA authorization. The denial would simply mean PMI cannot make the specific reduced-risk marketing claims it applied for. PMI could modify its application and resubmit, or appeal the decision.

Does this affect other nicotine pouch brands?

The specific MRTP application covers ZYN products specifically. However, if approved, it sets a precedent. Other brands would potentially be able to file their own MRTP applications based on similar science. A denial would also send a signal about the bar the FDA is setting for this kind of claim.

Where can I find more information about nicotine pouches and how they compare to cigarettes?

For an overview of how different nicotine pouch products compare and how they work, nicotine-pouches.org covers the category in depth. For official FDA announcements, the FDA's Center for Tobacco Products publishes updates at FDA.gov.

Sources and Further Reading